Hyloris Pharmaceuticals SA (EBR: HYL)
Belgium
· Delayed Price · Currency is EUR 5.82
-0.08 (-1.36%)
Sep 4, 2024, 2:30 PM CET
Hyloris Pharmaceuticals Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '23 Dec 31, 2023 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 |
| Revenue | 0.53 | 0.53 | 2.15 | 1.4 | 0.8 | 0.55 | Upgrade
|
| Revenue Growth (YoY) | -75.23% | -75.23% | 53.54% | 74.88% | 44.40% | 16.88% | Upgrade
|
| Cost of Revenue | 15.35 | 15.35 | 14.69 | 11.98 | 8.13 | 6.19 | Upgrade
|
| Gross Profit | -14.82 | -14.82 | -12.54 | -10.58 | -7.33 | -5.64 | Upgrade
|
| Selling, General & Admin | 15.73 | 15.73 | 13.74 | 13.18 | 5.41 | 3.9 | Upgrade
|
| Research & Development | 4.91 | 4.91 | 5.75 | 4.78 | 2.77 | 1.24 | Upgrade
|
| Operating Expenses | 20.65 | 20.65 | 19.49 | 17.95 | 8.18 | 5.14 | Upgrade
|
| Operating Income | -35.46 | -35.46 | -32.03 | -28.53 | -15.51 | -10.78 | Upgrade
|
| Interest Expense | -1.38 | -1.38 | -1.52 | -5.6 | -4.43 | -2.67 | Upgrade
|
| Interest & Investment Income | 0.97 | 0.97 | 0.06 | - | - | 0 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.19 | -0.19 | -0.02 | -0.1 | -0.04 | 0.01 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.02 | -0.02 | -0.03 | -0.02 | -0.01 | -0.01 | Upgrade
|
| Pretax Income | -36.07 | -36.07 | -33.54 | -34.25 | -19.99 | -13.44 | Upgrade
|
| Income Tax Expense | 0.11 | 0.11 | -0.77 | 0.07 | 0.02 | 0.04 | Upgrade
|
| Net Income | -36.18 | -36.18 | -32.77 | -34.31 | -20.01 | -13.48 | Upgrade
|
| Net Income to Common | -36.18 | -36.18 | -32.77 | -34.31 | -20.01 | -13.48 | Upgrade
|
| Shares Outstanding (Basic) | 30 | 30 | 30 | 9 | 4 | 3 | Upgrade
|
| Shares Outstanding (Diluted) | 30 | 30 | 30 | 9 | 4 | 3 | Upgrade
|
| Shares Change (YoY) | - | - | 218.23% | 163.40% | 19.35% | 12.68% | Upgrade
|
| EPS (Basic) | -1.20 | -1.20 | -1.09 | -3.62 | -5.56 | -4.47 | Upgrade
|
| EPS (Diluted) | -1.20 | -1.20 | -1.09 | -3.62 | -5.56 | -4.47 | Upgrade
|
| Free Cash Flow | -32.69 | -32.69 | -27.07 | -19.97 | -13.07 | -9.97 | Upgrade
|
| Free Cash Flow Per Share | -1.08 | -1.08 | -0.90 | -2.10 | -3.63 | -3.30 | Upgrade
|
| Operating Margin | -6665.98% | -6665.98% | -1491.06% | -2039.31% | -1939.13% | -1944.95% | Upgrade
|
| Profit Margin | -6800.94% | -6800.94% | -1525.70% | -2452.75% | -2501.75% | -2433.75% | Upgrade
|
| Free Cash Flow Margin | -6145.11% | -6145.11% | -1260.29% | -1427.09% | -1634.25% | -1799.46% | Upgrade
|
| EBITDA | -35.23 | -35.23 | -31.87 | -28.38 | -15.37 | -10.65 | Upgrade
|
| D&A For EBITDA | 0.23 | 0.23 | 0.16 | 0.15 | 0.14 | 0.12 | Upgrade
|
| EBIT | -35.46 | -35.46 | -32.03 | -28.53 | -15.51 | -10.78 | Upgrade
|
| Revenue as Reported | 0.53 | 0.53 | 2.15 | 1.4 | 0.8 | 0.55 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.